ADOCIA news, videos and press releases - Page 2
For more news please use our advanced search feature.
ADOCIA - More news...
ADOCIA - More news...
- Number of Shares and Voting Rights of ADOCIA as of October 31st, 2022
- ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates
- Number of Shares and Voting Rights of ADOCIA as of September 30th, 2022
- ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis
- ADOCIA: Upcoming Investor Meetings
- ADOCIA Announces First Half 2022 Financial Results and Provides a Business Update
- Adocia Will Release Its 2022 Half-year Results on September 19th and Hold a Webinar on September 20th
- Number of Shares and Voting Rights of ADOCIA as of August 31st, 2022
- ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes
- Number of Shares and Voting Rights of ADOCIA as of July 31st, 2022
- ADOCIA Reports Cash and Revenue for the Second Quarter and Provides Corporate Update
- Adocia Announces Half Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets
- Number of Shares and Voting Rights of ADOCIA as of June 30th, 2022
- Adocia Publishes its Letter to Shareholders
- ADOCIA Announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes
- ADOCIA confirms its eligibility for the PEA–PME
- Number of shares and voting rights of ADOCIA as of May 31st, 2022
- ADOCIA Announces its Annual Shareholders’ Meeting to Be Held on June 28, 2022 in Paris
- ADOCIA Reports Financial Results of First Quarter 2022 and Provides Corporate Update
- ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao
- Number of Shares and Voting Rights of ADOCIA as of April 30th, 2022
- ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao
- ADOCIA Announces the Release of its Universal Registration Document for the Year 2021
- ADOCIA Announces Its Annual Results for 2021 and Presents an Update on Activities
- Adocia: Number of Shares and Voting Rights of ADOCIA as of March 31st, 2022
- ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao
- Adocia strengthens its cash position by 19 million euros following a real estate transaction
- ADOCIA Strengthens Its Cash Position by 19 Million Euros Following a Real Estate Transaction
- Number of Shares and Voting Rights of Adocia as of February 28th, 2022
- ADOCIA Announces 2021 Fourth Quarter Financial Results
